Strategy Built for Clinical Exits.
We provide the strategic blueprints required to propel Biotech, MedTech, and HealthTech ventures from startup concepts to investor-ready clinical assets.
OUR EXPERTISE
Comprehensive advisory funnels.
Investor Readiness
Engineering the 'Executive Polish', from high-fidelity data rooms to rigorous valuation and pitch refinement.
Commercialization Roadmaps
Detailed milestone planning, GTM strategy, and regulatory mapping.
Funding Stack Optimization
Balancing dilutive VC capital with non-dilutive grants (SBIR/BAA) to minimize equity loss while maximizing runway.
FAQs
What exactly is 'Funding Stack Optimization'?
It is the strategic balancing of your capital sources. We help you identify how to utilize non-dilutive funding (like SBIR or BAA grants) to reach key technical milestones before raising dilutive venture capital, thereby protecting founder equity and increasing valuation.
How do you assist with 'Investor Readiness' for Oncology VCs?
Institutional oncology investors look for deep clinical moats. We help you prepare by auditing your data room, refining your scientific narrative for non-technical partners, and building rigorous financial models that reflect clinical trial costs and timelines.
Does your business planning cover both Biotech and MedTech?
Yes. We tailor our commercialization roadmaps to the vertical. For Biotech, we focus on clinical MoA and trial design. For MedTech and Diagnostics, we focus on human factors, hardware prototyping, and technical sensitivity/specificity requirements.
Yes. Part of our 'Investor Readiness' work involves mapping out FDA/EMA pathways and estimating reimbursement codes. Investors need to see that there is a clear, profitable exit path once clinical efficacy is proven.
Do you help with global regulatory and reimbursement strategy?
When is the best time for a founder to engage Caizio for strategic guidance?
Ideally, founders should engage us 6 to 12 months before their next major funding round or clinical milestone. This provides sufficient time to refine the strategy and build the 'Executive Polish' required for institutional capital.
Contact Us
Partner with us to engineer your business strategy, refine your investor readiness, and execute your growth milestones.